Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

DB Alex Brown Cuts Noven Pharmaceutical to 'Buy'

DB Alex Brown downgraded Noven Pharmaceutical (NOVN) to buy from strong buy.

Analyst David Steinberg says due to significantly lower international orders from partner Novartis AG for Estalis and Estradot, management expects $0.40-$0.45 2001 EPS. He notes no

guidance is given for 2002. As a result, he cut the $0.68 2001 EPS estimate to $0.45, and trimmed the $0.95 2002 estimate to $0.68. Steinberg also cut the $1.05 2003 estimate to $0.95. Steinberg downgraded due to lack of visibility. However, the analyst says his best guess is that Novartis will market these products in Europe, just not as quickly as hoped. In light of this new development, Steinberg ascribes net present value at $23 a share.

blog comments powered by Disqus